Drugs / foselutoclax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06011798 | Aug 2023 → Jan 2025 | diabetes mellitus, diabetic macular edema, macular retinal edema | Unity Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | foselutoclax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011798 ↗ |
| Route | Other | “10 μg foselutoclax (50 μl of 0.2 μg/μl solution) IVT on Day 1 and Weeks 8 and 16” NCT06011798 ↗ |